KEGG   DRUG: Margetuximab
Entry
D10446                      Drug                                   
Name
Margetuximab (USAN/INN);
Margetuximab-cmkb;
Margenza (TN)
Product
Formula
C6484H10010N1726O2024S42
Exact mass
145782.1685
Mol weight
145871.938
Sequence
(Heavy chain)
QVQLQQSGPE LVKPGASLKL SCTASGFNIK DTYIHWVKQR PEQGLEWIGR IYPTNGYTRY
DPKFQDKATI TADTSSNTAY LQVSRLTSED TAVYYCSRWG GDGFYAMDYW GQGASVTVSS
ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS
GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPELVGG
PSVFLLPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPPEEQYN
STLRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE
LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPLV LDSDGSFFLY SKLTVDKSRW
QQGNVFSCSV MHEALHNHYT QKSLSLSPGK
(Light chain)
DIVMTQSHKF MSTSVGDRVS ITCKASQDVN TAVAWYQQKP GHSPKLLIYS ASFRYTGVPD
RFTGSRSGTD FTFTISSVQA EDLAVYYCQQ HYTTPPTFGG GTKVEIKRTV AAPSVFIFPP
SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
(Disulfide bridge: H22-H96, H'22-H'96, L23-L88, L'23-L'88, L134-L194, L'134-L'194, H147-H203, H'147-H'203, H223-L214, H'223-L'214, H229-H'229, H232-H'232, H264-H324, H'264-H'324, H370-H428, H'370-H'428; Glycosylation site: Asn-H300, Asn-H'300)
  Type
Peptide
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03158  HER2 inhibitor
Remark
ATC code: L01FD06
Product: D10446<US>
Product (mixture): D12756<US>
Efficacy
Antineoplastic, Anti-HER2 antibody
  Disease
Breast cancer (HER2 positive) [DS:H00031]
  Type
Monoclonal antibody
Target
ERBB2* (HER2, CD340) [HSA_VAR:2064v1] [HSA:2064] [KO:K05083]
  Pathway
hsa04012  ErbB signaling pathway
hsa05200  Pathways in cancer
hsa05224  Breast cancer
  Network
nt06270  Breast cancer
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
     L01FD06 Margetuximab
      D10446  Margetuximab (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Margetuximab
    D10446  Margetuximab (USAN/INN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03158  HER2 inhibitor
     D10446  Margetuximab
Drug classes [BR:br08332]
 Antineoplastic
  DG03158  HER2 inhibitor
   D10446  Margetuximab
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
     D10446  Margetuximab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10446
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10446
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10446
Other DBs
CAS: 1350624-75-7
PubChem: 172232539
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system